Catal­ent re­port­ed a slight rev­enue up­swing dur­ing its lat­est quar­ter­ly re­sults, which CEO Alessan­dro Masel­li ...

Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

Gilead and Ar­cel­lx’s ear­ly tri­al da­ta on their mul­ti­ple myelo­ma cell ther­a­py show that pa­tients saw no cas­es of ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Health systems and hospitals across the US have been rolling out artificial intelligence tools to help doctors with administrative tasks like taking notes, coding visits, and responding ...

Promising data don’t always equal a stock pop. Viking Therapeutics presented what analysts thought were compelling data on an oral GLP-1/GIP dual agonist on Sunday ...

Sana Biotech­nol­o­gy is prun­ing its pipeline and head­count for the sec­ond time in around a year to stretch its cash and ...